T1G3R-1 Trial: Detectability and Prognostic Value of ctDNA in T1 G3 Bladder Cancer

May 14, 2026 updated by: University Hospital, Basel, Switzerland

T1G3 bladder cancer is a heterogeneous disease with a high risk of disease persistence after the first TUR-B, understaging, disease progression, bladder removal, and mortality.

Current risk stratification is insufficient and needs improvement. Ct-DNA could identify patients with disease persistence, progression and could monitor and tailor therapy. It might improve patient risk stratification, avoiding under- and overtreatment, reducing morbidity and mortality.

Primary objective is to investigate the detectability of ct-DNA in T1G3 urothelial bladder cancer patients and build a biobank through collection of different sample types (urine, plasma) in T1G3 bladder cancer patients which allows future retrospective testing.

Study Overview

Status

Recruiting

Conditions

Bladder Cancer

Study Type

Observational

Enrollment (Estimated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Heike Püschel
Phone Number: +41 61 55 65477
Email: Heike.Pueschel@usb.ch

Study Contact Backup

Name: Niklas Simon
Phone Number: +41 61 55 65616
Email: Niklas.Simon@usb.ch

Study Locations

Switzerland
- - Basel, Switzerland
    - Recruiting
    - Universitätsspital Basel
    - Contact:
      
      Heike Püschel
      
      Phone Number: +41 61 55 65477
      
      Email: Heike.Pueschel@usb.ch
    - Contact:
      
      Niklas Simon
      
      Phone Number: +41 61 55 65616
      
      Email: Niklas.Simon@usb.ch
    - Principal Investigator:
      
      Cyrill Rentsch
  - Lucerne, Switzerland
    - Recruiting
    - Luzerner Kantonsspital
    - Contact:
      
      Fabian Aschwanden
      
      Email: fabian.aschwanden@luks.ch
    - Contact:
      
      Tamara Lötscher
      
      Email: tamara.loetscher@luks.ch
    - Principal Investigator:
      
      Nico Grossmann

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Adult
Older Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

Patients with a proven T1G3 Bladder Cancer

Description

Inclusion Criteria:

patients > 18 years of age, able to give informed consent as documented by signature,
patients with a cystoscopically proven bladder cancer, suspicious for T1 stage, who will undergo TUR-B

Exclusion Criteria:

Patients with metastases or concomitant upper tract tumor at diagnosis will
Patients with non T1 G3 cancers
Patients with upstaging, either at re-TUR-B or after immediate radical cystectomy
Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
Vulnerable persons (e.g. < 18y of age, unable to consent to the study)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Detectability of ct-DNA in T1G3 urothelial bladder cancer patients Time Frame: From start of treatment 36 Months	Primary endpoint is the detectability of ct-DNA in T1G3 urothelial bladder cancer patients, whether there are dynamic changes during the different treatment steps (after TUR-BT, after re-TUR-BT, during instillation therapy) and if ct-DNA is predictive / prognostic in T1G3 urothelial bladder cancer patients.	From start of treatment 36 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Basel, Switzerland

Investigators

Principal Investigator: Cyrill Rentsch, Prof., Universitätsspital Basel

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 18, 2025

Primary Completion (Estimated)

June 1, 2030

Study Completion (Estimated)

June 1, 2030

Study Registration Dates

First Submitted

May 5, 2026

First Submitted That Met QC Criteria

May 5, 2026

First Posted (Actual)

May 12, 2026

Study Record Updates

Last Update Posted (Actual)

May 18, 2026

Last Update Submitted That Met QC Criteria

May 14, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

T1G3R-1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.